George M. Solomon
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
George M. Solomon has a total of 31 co-authors. Here are the top co-authors by number of shared publications:
- Steven Mark Rowe
Gregory Fleming James Cystic Fibrosis Research Center, University of Alabama at Birmingham, Birmingham, USA
3 shared publications Amit Gaggar
Department of Medicine
1 shared publication- Amit Gaggar
University of Alabama at Birmingham
1 shared publication - Andrew Nesmith
University of Alabama at Birmingham Department of Medicine, Birmingham, AL, USA
1 shared publication Bo Liu
Department of Medicine, The Gregory Fleming James Cystic Fibrosis Research Center, University of Alabama at Birmingham, Birmingham, AL, USA
1 shared publication- Brent Bermingham
University of Alabama at Birmingham Department of Medicine, Birmingham, AL, USA
1 shared publication
Latest Publications
- Top Cited PapersOpen Access
- 27 August 2024
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 134 (20)
Elexacaftor/tezacaftor/ivacaftor’s effects on cystic fibrosis infections are maintained, but not increased, after 3.5 years of treatment
- 27 August 2024
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 134 (20)
Top Cited PapersOpen AccessElexacaftor/tezacaftor/ivacaftor’s effects on cystic fibrosis infections are maintained, but not increased, after 3.5 years of treatment
- 1 September 2019
- Published by Elsevier in Journal of Cystic Fibrosis
- Vol. 18 (5) , 579-580
Taskforce recommends coordinated effort to improve clinical research conduct and find highly effective CFTR-directed treatment for rare mutations
- 1 September 2019
- Published by Elsevier in Journal of Cystic Fibrosis
- Vol. 18 (5) , 579-580
Taskforce recommends coordinated effort to improve clinical research conduct and find highly effective CFTR-directed treatment for rare mutations
- Open Access
- 25 April 2019
- Published by Springer Nature in BMC Pulmonary Medicine
- Vol. 19 (1) , 82
Employment of an algorithm of care including chest physiotherapy results in reduced hospitalizations and stability of lung function in bronchiectasis
There is a paucity of data on long term clinical effects of high frequency chest wall oscillation (HFCWO) in the Bronchiectasis population. Other therapies such as nebulized mucolytics and long term antibiotics have proven benefit on quality of life and exacerbation rate. In this study a treatment algorithm that included HFCWO as a component was initiated to see what the long term effects of the proposed algorithm were on lung function, antibiotic use, and exacerbation rates. This was an observational comparative retrospective cohort study from database of patients with Bronchiectasis. Patients with > 2 exacerbations and significant symptom burden were enrolled to receive a treatment algorithm. The algorithm included: nebulized bronchodilators, mucolytics (hypertonic saline (3–7%) or n-acetylcysteine) inhaled daily or twice daily, thrice weekly macrolide therapy when appropriate, and high frequency chest wall oscillation (HFCWO) therapy (daily to twice daily per issued protocol) Outcomes from the cohort were analyzed for the subsequent twelve months after initiation to observe longitudinal lung function and clinical outcomes. Chart review was then done to obtain data the year prior to the start of the algorithm in this same cohort of patients. Sixty-five patients received the Smart Vest® HFCWO system and were enrolled into the algorithm for treatment during the study period. Of the sixty-five patients, forty-three were eligible due to adequate 1-year baseline and follow up data at the time of the study initiation. The mean FEV1 remained stable at 1-year post enrollment (1.85 ± 0.60 L pre vs 1.89 ± 0.60 L post, p = NS) and the number of exacerbations requiring hospitalization was reduced (1.3 ± 1.0 pre vs. 0.46 ± 0.81 hospitalizations, post initiation, p < 0.0001). Antibiotic use overall was also reduced (2.5 ± 0.86 courses/year pre vs 2.1 ± 0.92 courses per year post initiation, p < 0.0001). Standardized care for Bronchiectasis involving an algorithm for Mucociliary clearance that centers on initiation of HFCWO may help to reduce lung function decline, need for oral antibiotics, and reduced hospitalization rate.
- 25 April 2019
- Published by Springer Nature in BMC Pulmonary Medicine
- Vol. 19 (1) , 82
Open AccessEmployment of an algorithm of care including chest physiotherapy results in reduced hospitalizations and stability of lung function in bronchiectasis
There is a paucity of data on long term clinical effects of high frequency chest wall oscillation (HFCWO) in the Bronchiectasis population. Other therapies such as nebulized mucolytics and long term antibiotics have proven benefit on quality of life and exacerbation rate. In this study a treatment algorithm that included HFCWO as a component was initiated to see what the long term effects of the proposed algorithm were on lung function, antibiotic use, and exacerbation rates. This was an observational comparative retrospective cohort study from database of patients with Bronchiectasis. Patients with > 2 exacerbations and significant symptom burden were enrolled to receive a treatment algorithm. The algorithm included: nebulized bronchodilators, mucolytics (hypertonic saline (3–7%) or n-acetylcysteine) inhaled daily or twice daily, thrice weekly macrolide therapy when appropriate, and high frequency chest wall oscillation (HFCWO) therapy (daily to twice daily per issued protocol) Outcomes from the cohort were analyzed for the subsequent twelve months after initiation to observe longitudinal lung function and clinical outcomes. Chart review was then done to obtain data the year prior to the start of the algorithm in this same cohort of patients. Sixty-five patients received the Smart Vest® HFCWO system and were enrolled into the algorithm for treatment during the study period. Of the sixty-five patients, forty-three were eligible due to adequate 1-year baseline and follow up data at the time of the study initiation. The mean FEV1 remained stable at 1-year post enrollment (1.85 ± 0.60 L pre vs 1.89 ± 0.60 L post, p = NS) and the number of exacerbations requiring hospitalization was reduced (1.3 ± 1.0 pre vs. 0.46 ± 0.81 hospitalizations, post initiation, p < 0.0001). Antibiotic use overall was also reduced (2.5 ± 0.86 courses/year pre vs 2.1 ± 0.92 courses per year post initiation, p < 0.0001). Standardized care for Bronchiectasis involving an algorithm for Mucociliary clearance that centers on initiation of HFCWO may help to reduce lung function decline, need for oral antibiotics, and reduced hospitalization rate.
- Open Access
- 14 February 2018
- Published by Springer Nature in BMC Pulmonary Medicine
- Vol. 18 (1) , 1-5
Implementation of a successful eradication protocol for Burkholderia Cepacia complex in cystic fibrosis patients
Infection with Burkholderia cepacia complex (Bcc) results in a heterogeneous clinical course ranging from asymptomatic colonization of the airways to fulminant respiratory failure in patients with cystic fibrosis (CF). Early eradication of Pseudomonas aeruginosa improves clinical outcomes. The efficacy and clinical outcomes following implementation of an eradication protocol for Bcc are less well understood. We developed and implemented a single center Bcc eradication protocol that included an intensive combination of intravenous, inhaled, and oral antibiotic therapies based on in vitro sensitivities. We conducted a retrospective cohort analysis of clinical outcomes compared to patients with chronic Bcc infection. Six patients were identified as having a newly acquired Bcc colonization and were placed on the eradication protocol. Sequential sputum samples after completion of the protocol demonstrated sustained clearance of Bcc in all patients. Lung function and nutritional status remained stable in the year following eradication. Clearance of Bcc from sputum cultures using a standardized protocol was successful at one year and was associated with clinical stability.
- 14 February 2018
- Published by Springer Nature in BMC Pulmonary Medicine
- Vol. 18 (1) , 1-5
Open AccessImplementation of a successful eradication protocol for Burkholderia Cepacia complex in cystic fibrosis patients
Infection with Burkholderia cepacia complex (Bcc) results in a heterogeneous clinical course ranging from asymptomatic colonization of the airways to fulminant respiratory failure in patients with cystic fibrosis (CF). Early eradication of Pseudomonas aeruginosa improves clinical outcomes. The efficacy and clinical outcomes following implementation of an eradication protocol for Bcc are less well understood. We developed and implemented a single center Bcc eradication protocol that included an intensive combination of intravenous, inhaled, and oral antibiotic therapies based on in vitro sensitivities. We conducted a retrospective cohort analysis of clinical outcomes compared to patients with chronic Bcc infection. Six patients were identified as having a newly acquired Bcc colonization and were placed on the eradication protocol. Sequential sputum samples after completion of the protocol demonstrated sustained clearance of Bcc in all patients. Lung function and nutritional status remained stable in the year following eradication. Clearance of Bcc from sputum cultures using a standardized protocol was successful at one year and was associated with clinical stability.
- 1 September 2017
- Published by Elsevier in Journal of Cystic Fibrosis
- Vol. 16 (5) , 573-578
A multiple reader scoring system for Nasal Potential Difference parameters
- 1 September 2017
- Published by Elsevier in Journal of Cystic Fibrosis
- Vol. 16 (5) , 573-578
A multiple reader scoring system for Nasal Potential Difference parameters
- 1 June 2017
- Published by Elsevier in Current Opinion in Pharmacology
- Vol. 34, 132-139
The therapeutic potential of CFTR modulators for COPD and other airway diseases
- 1 June 2017
- Published by Elsevier in Current Opinion in Pharmacology
- Vol. 34, 132-139
The therapeutic potential of CFTR modulators for COPD and other airway diseases
- 27 September 2014
- Published by Springer Nature
- p. 73-91
Functional Evaluation of Cystic Fibrosis Transmembrane Conductance Regulator
- 27 September 2014
- Published by Springer Nature
- p. 73-91
Functional Evaluation of Cystic Fibrosis Transmembrane Conductance Regulator